maraviroc API By Shanghai Yudiao Chemistry Technology Co., Ltd,
Pas encore membre de TradeKey.com? Inscrivez-vous pour vous connecter avec 9 millions d'importateurs et exportateurs.
Rejoignez-le maintenant c'est gratuit |
BOOK A CALL
Book Call On Your Favorite Time

By Signing Up. I agree to TradeKey.com Terms of Use, Privacy Policy, IPR and receive emails related to our services

Contact Us
product
Prev
maraviroc API
Next

maraviroc API

( Negotiable )

|

100 Gram Minimum Order

Pays:

China

N ° de modèle:

HIV02

Prix FOB:

( Negotiable ) Obtenir le dernier prix

Localité:

china

Prix de commande minimale:

-

Commande minimale:

100 Gram

Packaging Detail:

Aluminum foil bag, PTFE Bottle, or meet your requirment

Heure de livraison:

Within one week

Capacité de Fournir:

10 Kilogram per Month

Payment Type:

D/P, L/C, T/T

Groupe de produits :

Contacter maintenant
Membre gratuit

Personne à contacter Mr. James

Building A, NO.688,Qiushi Road,Jinshan District, Shanghai, shanghai

Contacter maintenant

Spécification du produit

  • Other Names: maraviroc
  • Type: Pharmaceutical Intermediates
  • Purity (%): 99%
  • Brand Name: YD
  • Application: Anti-HIV API
  • Appearance: white powder

La description

A panel of four CCR5 monoclonal antibodies (mAbs) recognizing different epitopes on CCR5 was examined in CCR*-mediated cell-cell fusion assay, alone or in combination with a variety of small molecule CCR5 antagonists. Although no antagonism was observed between any of the CCR5 inhibitors, surprisingly potent synergy was observed between CCR5 mAbs and antagonists, and the synergistic activity was confirmed in other antiviral assays. Strong synergy was also observed between CCR5 inhibitors and the human immunodeficiency virus (HIV) fusion inhibitor enfuvirtide. There was no synergy observed between small molecule CCR5 inhibitors; however, potent synergy was observed between mAbs recognizing different parts of CCR5. In all synergistic combinations, greater synergy was achieved at higher percent inhibition levels. A negative correlation was found between the degree of synergy between the two classes of CCR5 inhibitors and the ability to compete each other for binding to the receptor. For example, the greatest synergy, observed between the mAb ROAb*3 and the small molecule inhibitor maraviroc, did not interfere with binding to CCR5 for either inhibitor, whereas no synergy was found between mAb ****3 and maraviroc, which do compete for binding to CCR5. In addition, in contrast to a recent report, the CCR5 inhibitors tested here were found to inhibit the same stage of HIV entry. Based on the data presented here, we hypothesize that CCR5 inhibitors exert synergistic antiviral actions through a cobinding mechanism.

Pays: China
N ° de modèle: HIV02
Prix FOB: ( Negotiable ) Obtenir le dernier prix
Localité: china
Prix de commande minimale: -
Commande minimale: 100 Gram
Packaging Detail: Aluminum foil bag, PTFE Bottle, or meet your requirment
Heure de livraison: Within one week
Capacité de Fournir: 10 Kilogram per Month
Payment Type: D/P, L/C, T/T
Groupe de produits : API

Send a direct inquiry to this supplier

To:

Mr. James < Shanghai Yudiao Chemistry Technology Co., Ltd >

Je veux savoir: